[關(guān)鍵詞]
[摘要]
血管生成是惡性腫瘤的標(biāo)志之一，涉及血管內(nèi)皮細(xì)胞的增殖、遷移和細(xì)胞外基質(zhì)分解等多種途徑。血管內(nèi)皮生長(zhǎng)因子（VEGF）靶向抗腫瘤血管生成是臨床腫瘤治療的有效方法。木犀草素為黃酮類(lèi)化合物，具有抗腫瘤活性，可通過(guò)抑制VEGF及相關(guān)信號(hào)通路、抑制磷脂酰肌醇3-激酶/蛋白激酶B（PI3K/Akt）信號(hào)通路、抑制血管新生分子、抑制孕激素活性、靶向刺激Wnt信號(hào)通路、阻斷生長(zhǎng)停滯特異性蛋白6（Gas6）/受體酪氨酸激酶（Axl）信號(hào)通路而發(fā)揮抗腫瘤的血管生成作用。歸納了木犀草素抗腫瘤血管生成的作用機(jī)制，以期為木犀草素的臨床應(yīng)用提供參考。
[Key word]
[Abstract]
Angiogenesis is one of the hallmarks of malignant tumors, which involves the proliferation, migration, and extracellular matrix decomposition of vascular endothelial cells. Targeted anti-angiogenesis of vascular endothelial growth factor (VEGF) is an effective method for clinical tumor treatment. Luteolin is a flavonoid compound with various anti-tumor activities. Luteolin plays an anti-tumor angiogenesis role by inhibiting VEGF and related signal pathways, PI3K/Akt signal pathway, inhibiting angiogenesis molecules, inhibiting progesterone activity, targeting the stimulation of Wnt signal pathway, blocking Gas6/Axl signal pathway. This paper summarizes the anti-tumor angiogenesis mechanism of luteolin in order to provide reference for clinical application of luteolin.
[中圖分類(lèi)號(hào)]
R966
[基金項(xiàng)目]
河北省中醫(yī)藥管理局科研計(jì)劃項(xiàng)目（2018014）
